of patients in clinical trials, which could result in increased costs to us and could delay our development timeline.§We may never receive marketing approval for, or successfully commercialize,
of longer than six months in duration until ongoing preclinical toxicology studies are complete, which may lead to significant delays or the failure of gemcabene to obtain marketing approval.§Changes in regulatory requirements or U.S. Food and Drug Administration (FDA)
issued patents sufficient to protect gemcabene or any future product candidate, others could compete against us more directly.§We need to establish sales and marketing capabilities or enter into agreements
together with cash and cash equivalents, to fund: development costs associated with three late stage clinical trials of gemcabene for our target indications, our planned end of Phase 2 meetings with the FDA, manufacturing related activities,
cardiovascular outcomes trial, we will need substantial additional funds, and we cannot assure you that the results of any such outcomes trial or other clinical trials will be sufficient for approval.13Table of ContentsIf clinical trials of gemcabene or any future product candidate fail to demonstrate safety and
complete, the development and commercialization of such product candidate.Before obtaining marketing approval from regulatory authorities for the sale of gemcabene, we must complete preclinical development (including, but
Preclinical development and extensive clinical trials will also be required before obtaining marketing approval from regulatory authorities for any other product candidate we may pursue in the
ability to receive marketing approval or commercialize gemcabene or any other product candidate we may pursue in the future, including:§regulators or institutional review boards (IRBs) may not authorize us or our
receipt of necessary regulatory approvals could be delayed or prevented.We or our future collaborators may not be able to initiate or continue clinical trials for gemcabene or any future product candidate if we are unable
lacks sufficient efficacy, or that it causes undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization.Because gemcabene has been tested in relatively small patient populations and for limited durations to date, it is possible that our clinical trials
to conduct additional clinical trials, such as a cardiovascular outcomes trial prior to approval, the commercial prospects for gemcabene may be harmed and our ability to generate product revenue will
if we pursue and are able to successfully develop and obtain marketing approval of gemcabene and any future product candidate in broader patient populations, we likely will not be able to
developing gemcabene and initiating and completing our preclinical studies and clinical trials;§the cost, timing and outcome of our efforts to obtain marketing approval
development or regulatory review or approval process, and it may not increase the likelihood that a product candidate will receive marketing approval.Depending on the results of our late stage clinical trials, we may seek a breakthrough therapy designation for gemcabene or any other product
collaborators to obtain marketing approval of our product candidate and affect its pricing.In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
if approved, we could become subject to significant liability, which would adversely affect our business and financial condition.Risks Related to the Commercialization of Gemcabene or Any Future Product CandidateWe face substantial competition, which may result in others discovering, developing or
clinical trials and entering into strategic transactions, as well as in acquiring technologies complementary to, or necessary for, our programs.We lack experience commercializing products, which may have an adverse effect on our business.If gemcabene or any product candidate we may pursue in the future receives marketing approval, we will need to transition from a company with a
and our sales of such product candidate, if approved, may be limited, which would have an adverse effect on our operating results and financial condition.If we are not able to establish new collaborations on commercially reasonable terms, we may have to
extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed.Depending upon the timing, duration of regulatory review, and date of FDA marketing approval of gemcabene or any future product candidate, if any, one